The rise of personalised medicine is revolutionizing healthcare, prompting a re-evaluation of tradit...
Read moreThe German government’s proposal to keep negotiated confidential rebates was rejected by the feder...
Read moreNew biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...
Read moreProposed changes in Germany's pharma strategy suggest replacing publicly listed AMNOG rebates with c...
Read moreTibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...
Read moreGermany’s Health minister has announced that publicly listed AMNOG rebates could be replaced by co...
Read moreOur study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics ...
Read moreGermany is reshaping its Ministry of Health to prioritize the prevention of diseases like cancer, de...
Read moreEFPIA and VFA bosses state their concerns that the newly released EU Pharmaceutical Laws will furthe...
Read moreThe German government has released information regarding the 20% discounts to combination products e...
Read more